.jpg)
#ASCO25: Enhertu combo has the makings of a new standard in HER2-positive breast cancer
CHICAGO — AstraZeneca and Daiichi Sankyo’s Enhertu plus Roche’s Perjeta demonstrated the potential to shake up first-line treatment of some advanced breast cancers, according to a new study. In an interim analysis, patients with HER2-positive advanced ...
CHICAGO — AstraZeneca and Daiichi Sankyo’s Enhertu plus Roche’s Perjeta demonstrated the potential to shake up first-line treatment of some advanced breast cancers, according to a new study.
In an interim analysis, patients with HER2-positive advanced ...
